Combination therapy of the chimeric monoclonal anti-tumor necrosis factor α antibody (infliximab) with methotrexate in patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 17, Issue 6 SUPPL. 18, 1999, Pages

  Antoni, C ^a   Kalden, J R ^a,b,c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Institute for Clinical Immunology   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Combination treatment; Efficacy; Immunogenecity; Infliximab; Methotrexate; Rheumatoid arthritis; Side effects; Tumor necrosis factor

Indexed keywords

INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; IMMUNOGENICITY; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032695387     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993; 36: 1681-90.
2. ELLIOTT MJ, MAINI RN, FELDMANN M, LONG-FOX A, CHARLES P, BIJL H, WOODY JN: Repeated therapy with monoclonal antibody to tumor necrosis factor α. (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-7.
3. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α. (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
4. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
5. LIPSKY PE, ST CLAIR W, KAVANAUGH A et al.: Long-term control of signs and symptoms of rheumatoid arthritis with chimeric monoclonal anti-TNF α antibody (infliximab) in patients with active disease on methotrexate. Arthritis Rheum 1998; 41 (Suppl.).
6. MAINI RN, SMOLEN JS, BREEDVELD F et al: Long-term (1 year) results of a placebo-controlled, randomized phase III trial of infliximab (cA2, Remicade) combined with methotrexate in rheumatoid arthritis. Ann Rheum Dis 1999; Abstract book of EULAR 1999: p. 216.
7. PAULUS HE, EGGER MJ, WARD JR et al.: Analysis of improvement in individual rheumatoid arthritis patients treated with disease modifying drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990; 33: 477-484.
8. KLIPPEL JH (Ed.): Primer on the Rheumatic Diseases, 11th ed. 1997: 171-2.
9. CASH JM, KLIPPEL JR: Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994; 330: 1368-75.
10. WEINBLATT ME, POLISSON R, BLOTNER SD et al.: The effects of drug therapy on radiographic progression of rheumatoid arthritis: Results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993; 36: 613-9.
11. TUGWELL P, PINCUS T, YOCUM D et al.: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333: 137-41.
12. STEIN MC, PINCUS T, YOCUM D et al.: Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks. Arthritis Rheum 1997; 40: 1843-51.
13. O'DELL JR, HAIRE CE, ERIKSON N et al.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287-91.
14. WEINBLATT ME, KREMER JM, COBLYN JS et al.: Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1322-8.
15. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
16. FELSON DT, ANDERSON J, BOERS M et al.: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
17. BREEDVELD F, LIPSKY P, ST. CLAIR W et al.: A phase III randomized, double-blind, placebo-controlled study of infliximab (Remicade) in active RA despite methotrexate therapy: Safety of the ATTRACT trial. Ann Rheum Dis 1999; Abstract book of EULAR 1999: p. 216.
18. WOLFE F, MITCHELL DM, SIBLEY JT et al: The mortality of RA. Arthritis Rheum 1994; 37: 481-94.
19. SMOLEN J, STEINER G, BREEDVELD F et al: Anti-TNFα therapy and drug induced lupus-like syndrome. Ann Rheum Dis 1999; Abstract book of EULAR 1999: p. 217.
20. FELSON DT, ANDERSON JJ, LANGE MLM et al.: Should improvement in rheumatoid arthritis trials be defined as 50% or 70% improvement in core set measures, rather than 20% ? Arthritis Rheum 1997; 39 (Suppl.).
21. KALDEN-NEMETH D, GREBMEIER J, ANTONI C, MANGER B, WOLF F, KALDEN JR: NMR monitoring of rheumatoid arthritis patients receiving anti-TNFα monoclonal antibody therapy. Rheumatol Int 1997; 16: 249-55.
22. ANTONI C, MAINI RN, BREEDVELD F et al: Subgroup analyses show consistent clinical benefit in a 30-week, double-blind trial (ATTRACT) with an anti-TNFα monoclonal antibody (infliximab) in rheumatoid arthritis patients on methotrexate. Ann Rheum Dis 1999; Abstract book of EULAR 1999: p. 217.